Organon 

$0
625
+$0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30AprExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
0.63
0.76
0.88
1.01
Expected EPS
0.828833
Actual EPS
N/A

Financials

13.49%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
6.4BRevenue
864MNet Income

Analyst Ratings

$9.67Average Price Target
The highest estimate is 12.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
33%
Sell
67%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OGN WI. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap161.09B
Pfizer is a global pharmaceutical company that competes with Organon in the areas of women's health and biosimilars, making it a direct competitor.
Merck
MRK
Mkt Cap298.84B
Merck, the former parent company of Organon, competes in the pharmaceutical sector, including women's health and vaccine products.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie competes with Organon in the pharmaceuticals sector, particularly in women's health, with a focus on therapies and treatments.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson is a diversified healthcare giant that competes across various segments, including pharmaceuticals relevant to Organon's market.
AMGEN
AMGN
Mkt Cap187.56B
Amgen is a biopharmaceutical company that competes with Organon in the biosimilars market, offering alternative products.
Novo Nordisk
NVO
Mkt Cap164.13B
Novo Nordisk is a global healthcare company that, through its biopharmaceutical products, competes with Organon in areas like hormone replacement therapies.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap35.03B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing with Organon in the generics and women's health market.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb is a global biopharmaceutical company that competes with Organon in developing and commercializing prescription pharmaceuticals.
GSK
GSK
Mkt Cap113.29B
GlaxoSmithKline is a global healthcare company that competes with Organon in pharmaceuticals and vaccines, including areas of women's health.
Sanofi
SNY
Mkt Cap116.63B
Sanofi is a global biopharmaceutical company focusing on human health, competing with Organon in healthcare solutions, including women's health.

About

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1
Show more...
CEO
Ms. Carrie Smith Cox
Employees
10000
Country
GB

Listings

0 Comments

Share your thoughts

FAQ

What is Organon stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Organon stocks are traded under the ticker OGN WI.
When is the next Organon earnings date?
Organon is going to release the next earnings report on April 30, 2026.
What were Organon earnings last quarter?
OGN WI earnings for the last quarter are 0.63 USD per share, whereas the estimation was 0.73 USD resulting in a -13.34% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Organon revenue for the last year?
Organon revenue for the last year amounts to 6.4B USD.
What is Organon net income for the last year?
OGN WI net income for the last year is 864M USD.
How many employees does Organon have?
As of April 08, 2026, the company has 10,000 employees.
When did Organon complete a stock split?
Organon has not had any recent stock splits.
Where is Organon headquartered?
Organon is headquartered in Jersey City, GB.